#1 Clinical Trials Search in Europe

Adeno-Associated Viral Vector Serotype Rh10 Containing The Human Cholesterol 24-Hydroxylase Gene

This article discusses a groundbreaking clinical trial investigating the use of AB-1001, a gene therapy drug containing an adeno-associated viral vector with the human cholesterol 24-hydroxylase gene. The study aims to evaluate the safety, tolerability, and preliminary efficacy of this innovative treatment for adults with early manifest Huntington’s Disease (HD). This Phase I/II trial represents a significant step forward in the search for effective treatments for this debilitating genetic disorder.

Table of Contents

What is AB-1001?

AB-1001 is an innovative gene therapy being developed to treat Huntington’s disease, a rare and devastating inherited neurological disorder. This experimental treatment is also known by its scientific name: ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 CONTAINING THE HUMAN CHOLESTEROL 24-HYDROXYLASE GENE. It may also be referred to as AAVrh10.CAG.hCYP46A1.[1]

How Does AB-1001 Work?

AB-1001 is a type of gene therapy. It uses a harmless virus (adeno-associated virus, or AAV) to deliver a healthy copy of a specific gene (human CYP46A1) into the brain cells of people with Huntington’s disease. This gene is responsible for producing an enzyme that helps break down cholesterol in the brain. The hope is that by increasing the activity of this enzyme, it may help slow down or potentially reverse some of the damage caused by Huntington’s disease.[1]

Target Condition: Huntington’s Disease

Huntington’s disease is a genetic disorder that causes progressive brain damage. It leads to problems with movement, thinking, and psychiatric symptoms. Currently, there is no cure for Huntington’s disease, which is why new treatments like AB-1001 are so important to research.[1]

Clinical Trial Details

A clinical trial called ASK-HD-01-CS-101 is currently underway to study AB-1001. This is a Phase I/II trial, which means it’s one of the earliest stages of testing a new treatment in humans. The main goals are to check if the treatment is safe and to find the right dose to use in future studies.[1]

Eligibility Criteria

To participate in this study, patients must meet certain criteria. These include:

  • Being between 18 and 65 years old
  • Having a confirmed genetic test for Huntington’s disease
  • Being in the early stages of Huntington’s disease
  • Having brain structures (caudate and putamen) large enough for the treatment

Some conditions that would prevent participation include:

  • History of cancer that has spread
  • Active psychosis or confused state
  • History of stroke or brain bleeding
  • Active infections

These criteria help ensure the safety of participants and the reliability of the study results.[1]

Study Objectives

The main goals of this clinical trial are:

  1. To assess the safety and tolerability of AB-1001 when injected into specific areas of the brain (caudate nucleus and putamen)
  2. To determine the best dose for future studies
  3. To look for early signs that the treatment might be working

Researchers will measure various aspects of brain health and Huntington’s disease symptoms to see if AB-1001 has any positive effects.[1]

Potential Benefits

While it’s too early to know for sure if AB-1001 will be effective, researchers hope it might:

  • Slow down the progression of Huntington’s disease
  • Improve or stabilize brain volume in affected areas
  • Reduce levels of harmful proteins associated with the disease
  • Improve cognitive and motor function

These potential benefits will be carefully studied throughout the trial.[1]

Administration and Safety

AB-1001 is given as a suspension for injection directly into the brain. This procedure, called intracerebral administration, allows the treatment to reach the affected brain areas directly. As with any experimental treatment, there may be risks and side effects. The study will closely monitor participants for any adverse events, including serious side effects, for at least 52 weeks after treatment.[1]

It’s important to note that AB-1001 has been granted orphan drug designation (EU/3/19/2149) by regulatory authorities. This status is given to promising treatments for rare diseases to encourage their development.[1]

Aspect Details
Study Type Phase I/II, Open-Label, Dose Finding
Drug Name AB-1001 (AAVrh10.CAG.hCYP46A1)
Target Condition Early Manifest Huntington’s Disease
Administration Method One-time bilateral injection into caudate nucleus and putamen
Primary Objectives Assess safety, tolerability, and select optimal dose
Secondary Objectives Evaluate biomarkers and preliminary efficacy
Key Assessments MRI, cognitive tests, biomarker analysis, PET scans
Eligibility Criteria Adults 18-65, confirmed HD genetics, specific functional scores
Follow-up Period 52 weeks

FAQ

  • What is AB-1001 and how does it work? AB-1001 is a gene therapy drug that uses an adeno-associated viral vector to deliver the human cholesterol 24-hydroxylase gene. It is designed to be administered directly into specific brain regions affected by Huntington's Disease, potentially helping to address some of the underlying mechanisms of the disease.
  • Who is eligible for this clinical trial? The trial is open to adults aged 18-65 with early manifest Huntington's Disease. Participants must have genetic confirmation of HD, a specific functional capacity score, and meet certain brain imaging criteria. They should also have stable HD medications for at least 30 days before screening.
  • How is the drug administered in this trial? AB-1001 is administered through a one-time, bilateral injection into specific brain regions called the caudate nucleus and putamen. This targeted approach aims to deliver the therapy directly to areas most affected by Huntington's Disease.
  • What are the main objectives of this clinical trial? The primary objectives are to assess the safety and tolerability of AB-1001 and to determine the appropriate dose for future studies. Secondary objectives include evaluating key biomarkers and preliminary efficacy measures related to Huntington's Disease progression.
  • What kind of assessments will be done during the trial? The trial will involve various assessments, including monitoring for adverse events, brain imaging (MRI, MRS, and PET scans), functional and cognitive tests specific to HD, and analysis of biomarkers in blood and cerebrospinal fluid. These assessments will help researchers understand the effects of AB-1001 on disease progression and brain health.

Ongoing Clinical Trials on Adeno-Associated Viral Vector Serotype Rh10 Containing The Human Cholesterol 24-Hydroxylase Gene

  • Safety and Tolerability Study of AB-1001 Brain Injection in Adults with Early Huntington’s Disease

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Adeno-Associated Viral Vector: A harmless virus modified to deliver genetic material into cells, used in gene therapy to introduce therapeutic genes into target tissues.
  • Cholesterol 24-Hydroxylase Gene: A gene that produces an enzyme involved in cholesterol metabolism in the brain, which may play a role in Huntington's Disease.
  • Huntington's Disease (HD): A genetic disorder causing progressive brain damage, leading to movement, cognitive, and psychiatric symptoms.
  • CAG Expansion: A genetic mutation in the huntingtin gene, where a specific DNA sequence (CAG) is repeated more times than normal, causing Huntington's Disease.
  • UHDRS: Unified Huntington's Disease Rating Scale, a standardized assessment tool used to measure the progression and severity of Huntington's Disease.
  • Total Functional Capacity (TFC): A measure of a person's ability to perform daily activities and maintain independence, used in assessing Huntington's Disease progression.
  • Caudate Nucleus and Putamen: Specific regions in the brain that are particularly affected by Huntington's Disease and targeted for treatment in this study.
  • MRI (Magnetic Resonance Imaging): A medical imaging technique used to create detailed pictures of the brain and other body structures.
  • Biomarker: A measurable indicator of a biological state or condition, used to track disease progression or treatment effects.
  • Cerebrospinal Fluid (CSF): A clear fluid surrounding the brain and spinal cord, which can be analyzed for biomarkers related to neurological conditions.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-ab-1001-for-adults-with-early-huntingtons-disease/